Background:  A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients Trial Registration No: NCT01870778 (clinicaltrials.gov) Link  Trial Status: Recruitment stopped Randomized worldwide: 6800 patients Enrolling Centers:  542 centers Worldwide Core Study Team: 
Home News Team Current Studies Publications Events Cooperations Contact
© Christian Mueller, 2012 - 2017  │  Disclaimer  │  Imprint  │  Webmaster │ Last Update: August 2017
Dr. Beate Hartmann Dr. Samyut Shrestha Dr. Christian Puelacher